Higashikawa Toshihiro, Ito Tomohiko, Mizuno Takurou, Ishigami Keiichirou, Kohori Masaru, Mae Kunihiro, Sangen Ryusho, Usuda Daisuke, Saito Atsushi, Iguchi Masaharu, Kasamaki Yuji, Fukuda Akihiro, Saito Hitoshi, Kanda Tsugiyasu, Okuro Masashi
1 Kanazawa Medical University Himi Municipal Hospital, Kurakawa, Himi, Toyama, Japan.
2 Department of Geriatric Medicine, Kanazawa Medical University, Uchinada, Kahoku-gun, Ishikawa, Japan.
J Int Med Res. 2018 Dec;46(12):5117-5126. doi: 10.1177/0300060518790870. Epub 2018 Oct 25.
To assess the effect of 12 months of treatment with tofogliflozin on electrolytes and dehydration in Japanese patients with type 2 diabetes mellitus (T2DM).
This retrospective study involved mainly elderly patients with T2DM who had received tofogliflozin for 12 months. Data on glycated haemoglobin (HbA1c), serum electrolytes (sodium, potassium, chloride), haematocrit, estimated glomerular filtration rate (eGFR) and blood urea nitrogen (BUN)/creatinine ratio were retrieved and analysed.
Data from 69 patients (77% of whom were ≥65 years) showed that there was a significant reduction in HbA1c over the 12-month treatment period with tofogliflozin. However, the drug had no significant effect on levels of haematocrit, electrolytes, eGFR or BUN/creatinine ratio.
This retrospective analysis of data from mainly elderly Japanese patients with T2DM showed that 12-month administration of tofogliflozin exhibited glucose-lowering capabilities with accompanying low risk of electrolyte abnormalities and dehydration.
评估托格列净治疗12个月对日本2型糖尿病(T2DM)患者电解质及脱水情况的影响。
这项回顾性研究主要纳入了接受托格列净治疗12个月的老年T2DM患者。收集并分析糖化血红蛋白(HbA1c)、血清电解质(钠、钾、氯)、血细胞比容、估算肾小球滤过率(eGFR)及血尿素氮(BUN)/肌酐比值的数据。
69例患者(其中77%年龄≥65岁)的数据显示,在托格列净治疗的12个月期间,HbA1c显著降低。然而,该药物对血细胞比容、电解质、eGFR或BUN/肌酐比值水平无显著影响。
这项主要针对老年日本T2DM患者数据的回顾性分析表明,托格列净治疗12个月具有降糖能力,且伴随电解质异常和脱水的风险较低。